Choline PET based dose-painting in prostate cancer - Modelling of dose effects

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Niyazi, Maximilian ^a   Bartenstein, Peter ^a   Belka, Claus ^a   Ganswindt, Ute ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE;

ARTICLE; CANCER CONTROL; CANCER RISK; DOSE RESPONSE; INTENSITY MODULATED RADIATION THERAPY; MATHEMATICAL MODEL; POSITRON EMISSION TOMOGRAPHY; PROSTATE; PROSTATE CANCER; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; SCINTISCANNING; THEORETICAL MODEL;

HUMANS; MALE; MODELS, THEORETICAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 77952539668     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-23     Document Type: Article

References (70)

1. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics 2002, 53(5):1097-1105.
2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. International Journal of Radiation Oncology Biology Physics 1998, 41(3):491-500.
3. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. 2002, 427-435. Elsevier Science Inc.
4. Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, Luporsi E, Pommier P, Cowen D, Gonzague-Casabianca L, et al. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results. International Journal of Radiation Oncology Biology Physics 2000, 48(2):513-517.
5. Boersma LJ, Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. International Journal of Radiation Oncology Biology Physics 1998, 41(1):83-92.
6. Forman JD, Duclos M, Shamsa F, Porter AT, Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: Results of a dose escalation study. International Journal of Radiation Oncology Biology Physics 1996, 34(3):655-662.
7. Welz S, Nyazi M, Belka C, Ganswindt U. Surgery vs. radiotherapy in localized prostate cancer. Which is best?. Radiation Oncology 2008, 3. 10.1186/1748-717X-3-23, 2553076, 18775078.
8. Ganswindt U, Paulsen F, Anastasiadis AG, Stenzl A, Bamberg M, Belka C. 70 Gy or more: which dose for which prostate cancer?. J Cancer Res Clin Oncol 2005, 131(7):407-419. 10.1007/s00432-005-0681-0, 15887028.
9. Tanderup K, Olsen DR, Grau C. Dose painting: Art or science?. Radiotherapy and Oncology 2006, 79(3):245-248. 10.1016/j.radonc.2006.05.002, 16725221.
10. Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. ROLE OF INTENSITY-MODULATED RADIOTHERAPY IN REDUCING TOXICITY IN DOSE ESCALATION FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics 2009, 73(3):685-691.
11. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999, 44(4):921-929.
12. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001, 51(1):244-254.
13. Dogan N, Wu Y, Hagan MP. Simultaneous-integrated boost (SIB) IMRT for treatment of indermediate-risk prostate cancer with nodal irradiation. International Journal of Radiation Oncology Biology Physics 2006, 66(3):2805.
14. Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, Fichtinger G, Choyke PL, Xu S, Kruecker J, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiation Oncology 2007, 2. 10.1186/1748-717X-2-36, 2075521, 17877821.
15. Li X, Wang JZ, Jursinic P, Lawton CA. IMRT simultaneous integrated boost for high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics 2004, 60(1):2486.
16. Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, Eble MJ. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol 2009, 4:36. 10.1186/1748-717X-4-36, 2753361, 19772568.
17. Onal C, Topkan E, Efe E, Yavuz M, Sonmez S, Yavuz A. Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis. Radiat Oncol 2009, 4:14. 10.1186/1748-717X-4-14, 2684071, 19432953.
18. Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, Rosewall T, Warde PR, Catton CN. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol 2009, 4:50. 10.1186/1748-717X-4-50, 2777178, 19887007.
19. Guckenberger M, Baier K, Richter A, Vordermark D, Flentje M. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?. Radiat Oncol 2008, 3:3. 10.1186/1748-717X-3-3, 2253547, 18190681.
20. Ghadjar P, Vock J, Vetterli D, Manser P, Bigler R, Tille J, Madlung A, Behrensmeier F, Mini R, Aebersold DM. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol 2008, 3:35. 10.1186/1748-717X-3-35, 2613141, 18937833.
21. Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, Aebersold DM. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiotherapy and Oncology 2009, 91(2):237-242. 10.1016/j.radonc.2008.12.007, 19167121.
22. Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics 2005, 61(4):1251-1257.
23. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. International Journal of Radiation Oncology Biology Physics 2008, 72(3):799-807.
24. Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, Rouzaud M, Vees H, Zaidi H, Miralbell R. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol 2009, 4:34. 10.1186/1748-717X-4-34, 2749024, 19740429.
25. Yuen J, Rodrigues G, Trenka K, Coad T, Yartsev S, D'Souza D, Lock M, Bauman G. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. Radiat Oncol 2008, 3:1. 10.1186/1748-717X-3-1, 2249591, 18179695.
26. Groves AM, Win T, Ben Haim S, Ell PJ. Non-[F-18]FDG PET in clinical oncology. Lancet Oncology 2007, 8(9):822-830. 10.1016/S1470-2045(07)70274-7, 17765191.
27. Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imag 2009, 53(2):245-268.
28. Reske SN, Blumstein NM, Glatting G. [C-11]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(1):9-17. 10.1007/s00259-007-0530-2, 17828534.
29. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. Positron emission tomography for radiation treatment planning. Strahlentherapie Und Onkologie 2005, 181(8):483-499. 10.1007/s00066-005-1422-7, 16044216.
30. Ganswindt U, Paulsen F, Alber M, Bares R, Bamberg M, Belka C. Intensity-modulated radiotherapy (IMRT) for lymph node-positive patients in prostate cancer under consideration of C-11-choline-PET data - first clinical experiences. Strahlentherapie Und Onkologie 2006, 182:71-71.
31. Ciernik IF, Brown DW, Schmid D, Hany T, Egli P, Davis JB. 3D-Segmentation of the F-18-choline PET signal for target volume definition in radiation therapy of the prostate. Technology in Cancer Research & Treatment 2007, 6(1):23-30.
32. Stewart RD, Li XA. BGRT: Biologically guided radiation therapy - The future is fast approaching!. Medical Physics 2007, 34:3739-3751. 10.1118/1.2779861, 17985619.
33. Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. British Journal of Radiology 2006, 79:S16-S26. 10.1259/bjr/84072695, 16980681.
34. van Lin E, Futterer JJ, Heumink S, Vight LP, Hoffmann AL, Van Kollenburg P, Huisman HJJ, Scheenen TWJ, Witjes JA, Leer JWK, et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and H-1-spectroscopic MRI. International Journal of Radiation Oncology Biology Physics 2006, 65(1):291-303.
35. Cheung R, Tucker SL, Lee AK, De Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. 2005, 993-1002. Elsevier Science Inc.
36. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, et al. Comparison of alternative biochemical failure definitions' based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. International Journal of Radiation Oncology Biology Physics 2003, 57(4):929-943.
37. Kuban DA, Thames HD, Levy LB. Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapy. World Journal of Urology 2003, 21(4):253-264. 10.1007/s00345-003-0361-0, 12923658.
38. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer. Can one size fit all?. International Journal of Radiation Oncology Biology Physics 2003, 57(2 Supplement):S146-S147.
39. Munro TR, Gilbert CW. THE RELATION BETWEEN TUMOUR LETHAL DOSES AND THE RADIOSENSITIVITY OF TUMOUR CELLS. British Journal of Radiology 1961, 34(400):246-251. 10.1259/0007-1285-34-400-246, 13726846.
40. O'Rourke SFC, McAneney H, Hillen T. Linear quadratic and tumour control probability modelling in external beam radiotherapy. Journal of Mathematical Biology 2009, 58(4-5):799-817. 10.1007/s00285-008-0222-y, 18825382.
41. Garcia LM, Wilkins DE, Raaphorst GP. alpha/beta ratio: A dose range dependence study. International Journal of Radiation Oncology Biology Physics 2007, 67(2):587-593.
42. Fowler JF, Ritter MA, Fenwick JD, Chappell RJ. How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003; 55: 194-203. International Journal of Radiation Oncology Biology Physics 2003, 57(2):593-595.
43. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. International Journal of Radiation Oncology Biology Physics 2001, 50(4):1021-1031.
44. D'Souza WD, Thames HD. Is the alpha/beta ratio for prostate cancer low?. International Journal of Radiation Oncology Biology Physics 2001, 51(1):1-3.
45. Chappell R, Fowler J, Ritter M. New data on the value of alpha/beta - Evidence mounts that it is low. (vol 60, pg 2004). International Journal of Radiation Oncology Biology Physics 1002, 61(2):635-635.
46. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really?. Radiotherapy and Oncology 2005, 76(1):1-3. 10.1016/j.radonc.2005.06.009, 15990189.
47. Kal HB, Van Gellekom MPR. How low is the alpha/beta ratio for prostate cancer?. International Journal of Radiation Oncology Biology Physics 2003, 57(4):1116-1121.
48. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiotherapy and Oncology 2005, 75(1):74-82. 10.1016/j.radonc.2004.12.019, 15878104.
49. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer?. International Journal of Radiation Oncology Biology Physics 2003, 55(1):194-203.
50. Wang JZ, Li XA, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell. International Journal of Radiation Oncology Biology Physics 2003, 57(4):1101-1108.
51. Williams SG, Taylor JMG, Liu N, Tra Y, Duchesne GM, Kestin LL, Martinez A, Pratt GR, Sandler H. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. International Journal of Radiation Oncology Biology Physics 2007, 68(1):24-33.
52. Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. British Journal of Radiology 2008, 81(961):59-68. 10.1259/bjr/59827901, 18039721.
53. Tome WA, Fowler JF. On cold spots in tumor subvolumes. Medical Physics 2002, 29(7):1590-1598. 10.1118/1.1485060, 12148742.
54. Reske SN, Blumstein NM, Glatting G. Advancement of PET and PET/CT in prostate carcinoma. Urologe 2006, 45(6).
55. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M. The detection rate of [C-11]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(1):18-23. 10.1007/s00259-007-0581-4, 17891394.
56. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F. Detection of lymph-node metastases with integrated [C-11]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52(2):423-429. 10.1016/j.eururo.2007.03.032, 17397992.
57. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007, 48(6):932-945. 10.2967/jnumed.106.035774, 17504879.
58. Ganswindt U, Stenzl A, Bamberg M, Belka C. Adjuvant radiotherapy for patients with locally advanced prostate cancer - A new standard?. Eur Urol 2008, 54(3):528-542. 10.1016/j.eururo.2008.06.059, 18602742.
59. Ganswindt U, Belka C. Radiotherapy in prostate cancer. Urologe 2008, 47(9):1245-1254. 10.1007/s00120-008-1846-7, 18641965.
60. King CR, Kapp DS. Radiotherapy after prostatectomy: Is the evidence for dose escalation out there?. International Journal of Radiation Oncology Biology Physics 2008, 71(2):346-350.
61. Warkentin B, Stavrev P, Stavreva NA, Fallone BG. Limitations of a TCP model incorporating population heterogeneity. Physics in Medicine and Biology 2005, 50(15):3571-3588. 10.1088/0031-9155/50/15/006, 16030383.
62. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, et al. Detection and localization of prostate cancer: Correlation of C-11-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine 2005, 46(10):1642-1649.
63. Krengli M, Gaiano S, Mones E, Ballare A, Beldi D, Bolchini C, Loi G. Reproducibility of patient setup by surface image registration system in conformal radiotherapy of prostate cancer. Radiat Oncol 2009, 4:9. 10.1186/1748-717X-4-9, 2649941, 19232137.
64. Nyholm T, Nyberg M, Karlsson MG, Karlsson M. Systematisation of spatial uncertainties for comparison between a MR and a CT-based radiotherapy workflow for prostate treatments. Radiat Oncol 2009, 4:54. 10.1186/1748-717X-4-54, 2781017, 19919713.
65. Graf R, Wust P, Budach V, Boehmer D. Potentials of on-line repositioning based on implanted fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiat Oncol 2009, 4:13. 10.1186/1748-717X-4-13, 2683853, 19397824.
66. Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, Heide UA, van Vulpen M. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008, 3:15. 10.1186/1748-717X-3-15, 2430572, 18495016.
67. Boda-Heggemann J, Kohler FM, Wertz H, Ehmann M, Hermann B, Riesenacker N, Kupper B, Lohr F, Wenz F. Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT. Radiat Oncol 2008, 3:37. 10.1186/1748-717X-3-37, 2588616, 18986517.
68. Kim Y, Tome WA. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncologica 2008, 47(5):906-916. 10.1080/02841860701843050, 2794432, 18568486.
69. Kim Y, Tome WA. On the impact of functional imaging accuracy on selective boosting IMRT. Physica Medica 2009, 25(1):12-24. 10.1016/j.ejmp.2007.12.001, 2737461, 18206411.
70. Pieters BR, Kamer JB, van Herten YR, van Wieringen N, D'Olieslager GM, Heide UA, Koning CC. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008, 88(1):46-52. 10.1016/j.radonc.2008.02.023, 18378028.